Source: Eur Respir J 2006; 28: 138-143
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Hughes R. J., Jais X., Bonderman D., Suntharalingam J., Humbert M., Lang I., Simonneau G., Pepke-Zaba J.. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006; 28: 138-143

Member's Comments

No comment yet.

Related content which might interest you: Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2007; 30: 922-927 Year: 2007 Bosentan for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 Open label study of bosentan in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 706s Year: 2004 Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 23: 595-600 Year: 2004 Longterm survival of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2008 - Acute and chronic pulmonary thromboembolic disease Year: 2008 Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Source: Eur Respir J 2010; 36: 792-799 Year: 2010 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Vasodilator treatment in chronic thromboembolic pulmonary hypertension Source: Annual Congress 2003 - Update on chronic thromboembolic pulmonary hypertension Year: 2003 Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) Source: Eur Respir J 2015; 45: 1293-1302 Year: 2015 ERS statement on chronic thromboembolic pulmonary hypertension Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension Year: 2021 Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2015; 24: 272-282 Year: 2015 Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 Chronic thromboembolic pulmonary hypertension Source: Annual Congress 2007 - Update on venous thromboembolism Year: 2007 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011